Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS.

Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA.

J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6. Epub 2006 Dec 16. Review.

PMID:
18040831
2.

The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.

Chen G, Huang LD, Jiang YM, Manji HK.

J Neurochem. 1999 Mar;72(3):1327-30.

3.

Neuroprotective strategies for HIV-1 associated dementia.

Dou H, Kingsley JD, Mosley RL, Gelbard HA, Gendelman HE.

Neurotox Res. 2004;6(7-8):503-21. Review.

PMID:
15639783
4.

Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis.

Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, Maggirwar SB, Dewhurst S, Gelbard HA, Gendelman HE.

J Neurosci. 2003 Oct 8;23(27):9162-70.

5.

HIV-1-associated central nervous system dysfunction.

Krebs FC, Ross H, McAllister J, Wigdahl B.

Adv Pharmacol. 2000;49:315-85. Review.

PMID:
11013768
6.

Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons.

Hall AC, Brennan A, Goold RG, Cleverley K, Lucas FR, Gordon-Weeks PR, Salinas PC.

Mol Cell Neurosci. 2002 Jun;20(2):257-70.

PMID:
12093158
7.
8.

GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid.

Jonathan Ryves W, Dalton EC, Harwood AJ, Williams RS.

Bipolar Disord. 2005 Jun;7(3):260-5.

9.

Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death.

Jin N, Kovács AD, Sui Z, Dewhurst S, Maggirwar SB.

Neuropharmacology. 2005 Mar;48(4):576-83. Epub 2005 Jan 25.

PMID:
15755485
10.

Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons.

Sui Z, Sniderhan LF, Fan S, Kazmierczak K, Reisinger E, Kovács AD, Potash MJ, Dewhurst S, Gelbard HA, Maggirwar SB.

Eur J Neurosci. 2006 May;23(10):2623-34.

PMID:
16817865
11.

Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.

Medina M, Avila J.

Curr Pharm Des. 2010;16(25):2790-8. Review.

PMID:
20698823
12.

Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways.

Hu JP, Xie JW, Wang CY, Wang T, Wang X, Wang SL, Teng WP, Wang ZY.

Brain Res Bull. 2011 May 30;85(3-4):194-200. doi: 10.1016/j.brainresbull.2011.03.006. Epub 2011 Mar 22.

PMID:
21435383
13.

Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.

Gould TD, Picchini AM, Einat H, Manji HK.

Curr Drug Targets. 2006 Nov;7(11):1399-409. Review.

PMID:
17100580
14.

Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation.

Thotala DK, Hallahan DE, Yazlovitskaya EM.

Cancer Res. 2008 Jul 15;68(14):5859-68. doi: 10.1158/0008-5472.CAN-07-6327. Erratum in: Cancer Res. 2008 Oct 1;68(19):8189.

15.

Up-regulation of protein L-isoaspartyl methyltransferase expression by lithium is mediated by glycogen synthase kinase-3 inactivation and beta-catenin stabilization.

Lamarre M, Desrosiers RR.

Neuropharmacology. 2008 Oct;55(5):669-76. doi: 10.1016/j.neuropharm.2008.05.033. Epub 2008 Jun 6.

PMID:
18582478
17.

Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.

Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, Muñoz-Fernández MA.

Pediatrics. 2003 Feb;111(2):E168-75.

PMID:
12563091
18.
19.

Absence of the inducible form of nitric oxide synthase in the brains of patients with the acquired immunodeficiency syndrome.

Bagasra O, Bobroski L, Sarker A, Bagasra A, Saikumari P, Pomerantz RJ.

J Neurovirol. 1997 Apr;3(2):153-67.

PMID:
9111178
20.

The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy.

Palomo V, Perez DI, Gil C, Martinez A.

Curr Med Chem. 2011;18(20):3028-34. Review.

PMID:
21651477
Items per page

Supplemental Content

Write to the Help Desk